Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.
- Primary indication
- Zinc dibutyldithiocarbamate is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.Curator reviewed
- Formula / weight
- C18H36N2S4Zn · 474.12 g/mol (avg)
- First approval
- United States, 2012
- Also known as
- (T-4)-bis(dibutylcarbamodithioato-κS,κS')zinc · bis(dibutyldithiocarbamato)zinc · dibutyldithiocarbamate zinc salt · zinc bis(dibutyldithiocarbamate) · zinc bis(dibutyldithiocarbamoyl)disulfide
Resolves to
Clinical / RWD
Structure
InChIKey
BOXSVZNGTQTENJ-UHFFFAOYSA-LSMILES[Zn++].CCCCN(CCCC)C([S-])=S.CCCCN(CCCC)C([S-])=STargets
What you can answer from here — as of July 07, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Zinc dibutyldithiocarbamate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account